Drugs / Codrituzumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04928677 | Jun 2021 → Jun 2027 expected | — | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT00976170 | Sep 2009 → Jul 2013 | hepatocellular carcinoma | Chugai Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT00746317 | Sep 2008 → Oct 2010 | hepatocellular carcinoma | Chugai Pharmaceutical | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT01507168 | Feb 2012 → Aug 2015 | hepatocellular carcinoma | Hoffmann-La Roche | Completed | Missed primary |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Codrituzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04928677 ↗ |
| Known as | GC33 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00746317 ↗ |
| Known as | RG-7686 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298089 ↗ |
| Known as | RO5137382 | “GC33(RO5137382)” NCT00976170 ↗ |
| Action | Inhibit | “Glypican-3 inhibitor” CHEMBL4298089 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4298089 ↗ |
| Route | Intravenous | “IV administration at 4 escalating dose levels.” NCT00746317 ↗ |
| Target | GPC3 | “Glypican-3 inhibitor” CHEMBL4298089 ↗ |